Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 9, 2020
Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaAmandeep Salhotra, Dongyun Yang, Sally Mokhtari, et al.
American Journal of Hematology|July 7, 2020
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemiaIbrahim Aldoss, Jianying Zhang, Matthew Mei, et al.
The Lancet. Haematology|July 27, 2024
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 studyAlex F Herrera, Jasmine Zain, Kerry J Savage, et al.
Blood Advances|January 10, 2019
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimenHaris Ali, Ibrahim Aldoss, Dongyun Yang, et al.
American Journal of Hematology|March 18, 2026
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell LymphomaGeoffrey Shouse, Matthew Matasar, Lu Chen, et al.
Bone Marrow Transplantation|November 8, 2019
Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosisRohan Gupta, Faizi Jamal, Dongyun Yang, et al.
Transplantation and Cellular Therapy|March 30, 2021
Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage TherapiesIbrahim Aldoss, Dongyun Yang, Monzr M Al Malki, et al.
Blood|June 20, 2023
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockadeMatthew Mei, Lu Chen, James Godfrey, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2018
Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell TransplantationMonzr M Al Malki, Nitya Nathwani, Dongyun Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity ModelMax J Gordon, Andy Kaempf, Andrea Sitlinger, et al.
Pageof 8